Screening for Neonatal Hyperbilirubinemia-First Do No Harm?
- PMID: 31107538
- PMCID: PMC6688481
- DOI: 10.1001/jamapediatrics.2019.1194
Screening for Neonatal Hyperbilirubinemia-First Do No Harm?
Conflict of interest statement
Conflict of Interest Disclosures:
Dr Botkin reports serving on the Ethics Advisory Board for Illumina Co with compensation. Drs Grosse and Prosser report association with the Evidence Review Group of the federal Advisory Committee for Heritable Disorders in Newborns and Children. No other disclosures were reported.
Comment in
-
Avoiding Harm From Hyperbilirubinemia Screening-Reply.JAMA Pediatr. 2019 Dec 1;173(12):1209-1210. doi: 10.1001/jamapediatrics.2019.3762. JAMA Pediatr. 2019. PMID: 31589244 Free PMC article. No abstract available.
-
Avoiding Harm From Hyperbilirubinemia Screening.JAMA Pediatr. 2019 Dec 1;173(12):1209. doi: 10.1001/jamapediatrics.2019.3765. JAMA Pediatr. 2019. PMID: 31589245 No abstract available.
-
Avoiding Harm From Hyperbilirubinemia Screening.JAMA Pediatr. 2019 Dec 1;173(12):1208-1209. doi: 10.1001/jamapediatrics.2019.3759. JAMA Pediatr. 2019. PMID: 31589273 No abstract available.
References
-
- Muchowski KE. Evaluation and treatment of neonatal hyperbilirubinemia. Am Fam Physician. 2014;89(11):873–878. - PubMed
-
- Health Services and Resources Administration Federal Advisory Committees. Previously nominated conditions table: conditions added to the Recommended Uniform Screening Panel (RUSP) by the Secretary. https://www.hrsa.gov/advisory-committees/heritable-disorders/rusp/previo.... Published August 2018. Accessed April 11, 2019.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
